- No special monitoring is needed.
- Very close and ongoing monitoring of patients for adverse effects and therapeutic levels is required.
- The drug is too dangerous to be approved.
- The drug is extremely safe.
118. A new medicinal drug is found to have a very narrow therapeutic window (small difference between effective and toxic doses). What critical implication does this have for pharmacovigilance?
Facebook
WhatsApp
